Table 1 Patient characteristics on admission, exposures during the ICU stay and outcomes of the entire populationa
Characteristics on admission | Total (N =850) |
|---|---|
Age (yr) | 59.8 (17.3) |
Male sex | 519 (61.1) |
Pre-ICU stay (days) | 4.6 (12.2) |
Prior antibiotic (≤1 mo) | 258 (30.4) |
APACHE II score | 20 (6.5) |
SOFA score | 6.4 (3.6) |
Shock on admission | 151 (17.8) |
Reason for admission | |
Infection | 486 (57.2) |
CNS disease | 99 (11.6) |
Postsurgical | 80 (9.4) |
Cardiovascular disease | 66 (7.8) |
Respiratory disease | 28 (3.3) |
Others | 91 (10.7) |
Underlying diseases | |
Diabetes mellitus | 157 (18.5) |
Haematological malignancy | 114 (13.4) |
Solid malignancy | 85 (10) |
COPD | 138 (16.2) |
Othersb | 193 (19.2) |
Prior corticosteroids (≤1 mo) | 156 (18.4) |
Immunosuppressive therapy | 90 (10.6) |
Exposures during ICU stay | |
Central venous catheter | 833 (98) |
Bladder catheter | 800 (94.1) |
Nasogastric tube | 573 (67.4) |
Enteral nutrition | 253 (29.8) |
Parenteral nutrition | 177 (20.8) |
Orotracheal intubation | 511 (60.1) |
Tracheostomy | 158 (18.6) |
Endoscopy | 121 (34.2) |
Surgery | 189 (22.2) |
Renal replacement therapies | 77 (9.1) |
Packed red blood cell transfusion | 291 (34.2) |
Any antibiotic | 746 (87.8) |
Any non-antipseudomonal antibiotic | 593 (69.8) |
Any antipseudomonal antibiotic: | 576 (67.8%) |
Carbapenem | 281 (33.1) |
Quinolone | 306 (36) |
Ceftazidime | 103 (12.1) |
Piperacillin-tazobactam | 180 (21.2) |
Amikacin | 52 (6.1) |
Outcomes | |
Length of stay (days) | 9.5 (10.3) |
In-ICU mortality | 117 (13.8) |
In-hospital mortality | 201 (23.6) |